2021
DOI: 10.1016/j.conctc.2021.100728
|View full text |Cite
|
Sign up to set email alerts
|

Enablers and hindrances for longer-term abstinence in opioid dependent individuals receiving treatment with extended-release naltrexone: A Norwegian longitudinal recovery trial (NaltRec study)

Abstract: Opioid-dependence is a comprehensive, relapsing disorder with negative individual, - family, - and societal consequences. Recovery is difficult to achieve. Research has shown reduced substance use and improved health- and psychosocial factors with extended-release naltrexone (XR-NTX) treatment. Pharmacological treatment should include psychosocial interventions to improve longer-term recovery. This study explores how voluntary monthly treatment with extended-release naltrexone hydrochloride (Vivitrol®) will in… Show more

Help me understand this report

Search citation statements

Order By: Relevance

Paper Sections

Select...
3
1
1

Citation Types

0
11
0

Year Published

2021
2021
2024
2024

Publication Types

Select...
6

Relationship

0
6

Authors

Journals

citations
Cited by 6 publications
(11 citation statements)
references
References 55 publications
0
11
0
Order By: Relevance
“…The current qualitative study is a substudy nested within "Long acting naltrexone for opioid addiction: the importance of mental, physical and societal factors for sustained abstinence and recovery" (NaltRec), a naturalistic, multicenter, open-label trial of treatment with extended-release naltrexone hydrochloride injectable suspension (Vivi-trol®). Weimand et al (2021) describes NaltRec in detail. Briefly, the study included 162 men or women, age 18-65 years, with a diagnosis of opioid dependence.…”
Section: Methodsmentioning
confidence: 99%
See 1 more Smart Citation
“…The current qualitative study is a substudy nested within "Long acting naltrexone for opioid addiction: the importance of mental, physical and societal factors for sustained abstinence and recovery" (NaltRec), a naturalistic, multicenter, open-label trial of treatment with extended-release naltrexone hydrochloride injectable suspension (Vivi-trol®). Weimand et al (2021) describes NaltRec in detail. Briefly, the study included 162 men or women, age 18-65 years, with a diagnosis of opioid dependence.…”
Section: Methodsmentioning
confidence: 99%
“…Furthermore, the NaltRec study was approved by the Norwegian Medicine Agency (NOMA), EudraCT Number 2017-004706-18, and personal data protection representative of each of the participating hospitals. The trial is registered on Clinicaltrials.gov # NCT03647774, first registered: Aug 28, 2018, before the first participant was included on Sep 21, 2018 (Weimand et al, 2021).…”
Section: Ethicsmentioning
confidence: 99%
“…Treatment with XR-NTX was not generally available in Norway when the study was conducted. For further details on the NaltRec study, see Weimand et al [ 1 ].…”
Section: Methodsmentioning
confidence: 99%
“…The opioid antagonist extended-release naltrexone (XR-NTX) blocks the effects of opioids and is a promising, safe and effective [ 1 ], treatment for patients with opioid use disorder (OUD) [ 2 4 ]. By its long-acting effect it offers an opportunity for persistent abstinence from all opioids, including agonist medication prescribed through opioid treatment programs (OTPs).…”
Section: Introductionmentioning
confidence: 99%
“…This study was built upon baseline data from the Norwegian NaltRec study (“Long acting naltrexone for opioid addiction: the importance of mental, physical, and societal factors for sustained abstinence and recovery”) [ 14 ], an open label multi-centre study carried out at five urban addiction clinics across Southern Norway (Akershus University Hospital, Sørlandet Hospital, Vestfold Hospital, Oslo University Hospital, and Haukeland University Hospital). It is a phase IV study on extended-release naltrexone (XR-NTX) in the treatment and recovery of patients with opioid dependence qualifying for OMT in a naturalistic setting.…”
Section: Methodsmentioning
confidence: 99%